Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2003-02-06
2004-10-12
Tsang, Cecilia (Department: 1626)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S490000, C544S282000, C544S283000, C514S258100
Reexamination Certificate
active
06803055
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to microencapsulated 1,2-benzazoles and their use in the treatment of warm blooded animals suffering from mental illness. More particularly, the present invention relays to microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and
1,2-benzisothiazoles and their use in treatment of mental patients.
2. Description of the Related Art Strupczewski et al., in U.S. Pat. No. 4,352,811 and U.S. Pat. No. 4,458,076, describe 3-piperidinyl-1,2-benzisoxazoles and 3-piperidinyl-1,2-benziothiazoles having antipsychotic and analgesic properties.
Kennis et al., U.S. Pat. No. 4,804,663, disclose 3-piperidinyl-1,2-benzisothiazoles and 3-piperidinyl-1,2-benzisoxazoles and their pharmaceutically acceptable acid addition salts that have antipsychotic properties and are useful in the treatment of a variety of complaints in which serotonin release is of predominant importance. In particular, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl) ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (“Risperidone”) is disclosed.
Janssen et al., U.S. Pat. No. 5.158,952, 3-piperidinyl-1,2-benzisoxazoles having long-acting antipsychotic properties and which are useful in the treatment of warm-blooded animals suffering from psychotic diseases. In particular, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (“9-hydroxy-Risperidone”) is disclosed.
A number of methods are known by which compounds can be encapsulated in the form of microparticles. In many of these processes, the material to be encapsulated is dispersed in a solvent containing a wall forming material. At a single stage of the process, solvent is removed from the microparticles and thereafter the microparticle product is obtained.
An example of a conventional microencapsulation process and microparticles produced thereby is disclosed in U.S. Pat. No. 3,737,337, incorporated by reference herein, wherein a solution of a wall or shell forming polymeric material in a solvent is prepared. The solvent is only partially miscible in water. A solid or core material is dissolved or dispersed in the polymer-containing solution and, thereafter, the core-material-containing solution is dispersed in an aqueous liquid that is immiscible in the organic solvent in order to remove solvent from the microparticles.
Another example of a process in which solvent is removed from microparticles containing a substance is disclosed in U.S. Pat. No. 3,523,906. In this process a material to be encapsulated is emulsified in a solution of a polymeric material in a solvent that is immiscible in water and then the emulsion is emulsified in an aqueous solution containing a hydrophilic colloid. Solvent removal from the microparticles is then accomplished by evaporation and the product is obtained.
In still another process as shown in U.S. Pat. No. 3,691,090 organic solvent is evaporated from a dispersion of microparticles in an aqueous medium, preferably under reduced pressure.
Similarly, the disclosure of U.S. Pat. No. 3,891,570 shows a method in which solvent from a dispersion of microparticles in a polyhydric alcohol medium is evaporated from the microparticles by the application of heat or by subjecting the microparticles to reduced pressure.
Another example of a solvent removal process is shown in U.S. Pat. No. 3,960,757.
Tice et al., in U.S. Pat. No. 4,389,330, describe the preparation of microparticles containing an active agent—which may, inter alia, be a psychotherapeutic agent—by a method comprising: (a) dissolving or dispersing an active agent in a solvent and dissolving a wall forming material in that solvent; b) dispersing the solvent containing the active agent and wall forming material in a continuous-phase processing medium; (c) evaporating a portion of the solvent from the dispersion of step (b), thereby forming microparticles containing the active agent in the suspension; and (d) extracting the remainder of the solvent from the microparticles.
Tice et al., in U.S. Pat. No. 4,530,840, describe the preparation of microparticles containing an anti-inflammatory active agent by a method comprising: (a) dissolving or dispersing an anti-inflammatory agent in a solvent and dissolving a biocompatible and biodegradable wall forming material in that solvent; (b) dispersing the solvent containing the anti-inflammatory agent and wall forming material in a continuous-phase processing medium; (c) evaporating a portion of the solvent from the dispersion of step (b), thereby forming microparticles containing the anti-inflammatory agent in the suspension: and (d) extracting the remainder of the solvent from the microparticles.
SUMMARY OF THE INVENTION
The present invention relates to microencapsulated 1,2-benzazoles and their use in the treatment of warm blooded animals suffering from mental disease. In a preferred embodiment. the invention relates to a pharmaceutical composition designed for the controlled release of an effective amount of a drug over an extended period of time, prepared in microparticle form. This composition comprises at least one antipsychotic agent and at least one biocompatible, biodegradable encapsulating polymer.
More particularly, the present invention relates to a method of treating warm blooded animal suffering from psychotic disorders comprising the administration thereto of a pharmaceutically effective amount of a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula
and the pharmaceutically acceptable acid addition salts thereof, wherein
R is hydrogen or alkyl of 1 to 6 carbon atoms;
R
1
and R
2
are independently selected from the group consisting of hydrogen, halo, hydroxy, alkyloxy of 1 to 6 carbon atoms, and C alkyl of 1 to 6 carbon atoms;
X is O or S;
Alk is C
1-4
alkanediyl; and
Q is a radical of formula
wherein
R
1
is hydrogen or alkyl of 1 to 6 carbon atoms:
Z is —S—, —CH
2
—, or —CR
4
═CR
5
—: where R
4
and R
5
are independently selected from the group consisting of hydrogen or alkyl of 1 to 6 carbon atoms;
A is a bivalent radical —CH
2
—CH
2
—, —CH
2
—CH
2
—CH
2
— or CR
6
═CR
7
—; where R
6
and R
7
are independently selected from the group consisting of hydrogen, halo, amino or alkyl of 1 to 6 carbon atoms; and
R
8
is hydrogen or hydroxyl;
within a polymeric matrix.
In another aspect, the present invention relates to a pharmaceutical composition comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of Formula I within a polymeric matrix.
In still another aspect, the present invention relates to a method of inhibiting serotonergic or dopaminergic overstimulation in animals wherein said method comprises administration of a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of Formula I within a polymeric matrix.
REFERENCES:
patent: 3197180 (1965-07-01), Bates et al.
patent: 3523906 (1970-08-01), Vrancken et al.
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3737337 (1973-06-01), Schnoring et al.
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3891570 (1975-06-01), Fukushima et al.
patent: 3923288 (1975-12-01), King et al.
patent: 3960757 (1976-06-01), Morishita et al.
patent: 4034965 (1977-07-01), King
patent: 4111402 (1978-09-01), Barbini
patent: 4128641 (1978-12-01), Itil
patent: 4201482 (1980-05-01), Imhauser et al.
patent: 4208136 (1980-06-01), King et al.
patent: 4329331 (1982-05-01), Kallick et al.
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4337261 (1982-06-01), Shutske et al.
patent: 4342870 (1982-08-01), Kennis et al.
patent: 4352811 (1982-10-01), Strupczewski
patent: 4389330 (1983-06-01), Tice et al.
patent: 4443451 (1984-04-01), Kennis et al.
patent: 4458076 (1984-07-01), Strupczewski
patent: 4485107 (1984-11-01), Kennis et al.
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4511258 (1985-04-01), Federighi et al.
paten
Atkins Thomas J.
Mesens Jean
Rickey Michael E.
Alkermas Controlled Therapeutics Inc. II
Covington & Burling
Reister Andrea G.
Sackey Ebenezer
Tsang Cecilia
LandOfFree
Microencapsulated 3-piperidinyl-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microencapsulated 3-piperidinyl-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated 3-piperidinyl-substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3304079